Related Experiment Video
Updated: Mar 23, 2026
04:04
Lateral Molar Approach-Driven Transoral Endoscopic Procedure for Benign Infratemporal Fossa Tumor Resection
Published on: August 15, 2025
631
Inflammatory pseudotumour of the maxilla
A Kichenaradjou1,2, A W Barrett3, P Norris4
1Department of Maxillofacial Surgery, Queen Victoria Hospital, East Grinstead, West Sussex, RH19 3DZ, UK. akichen@doctors.net.uk.
Oral and Maxillofacial Surgery
|April 8, 2016
Summary
Inflammatory pseudotumour (IP), a rare maxillofacial lesion, presents diagnostic challenges. Treatment response varies, with some patients experiencing aggressive disease progression despite therapy.
Area of Science:
- Oral and Maxillofacial Pathology
- Oncology
- Immunology
Background:
- Inflammatory pseudotumour (IP), also known as inflammatory myofibroblastic tumour (IMT), is a rare lesion affecting the maxillofacial skeleton.
- It is often a diagnosis of exclusion, requiring careful histopathological evaluation.
Observation:
- This study presents three cases of IP in the maxilla: two women and one man, aged 67, 56, and 70 years.
- Histopathological features were typical but non-specific, with variable IgG4-positive plasma cells and no ALK-1 expression.
- Patient demographics and treatment responses varied significantly.
Findings:
- Two female patients responded to steroids and radiotherapy, with one requiring azathioprine.
- The male patient experienced intracranial spread and succumbed to the disease despite aggressive treatment including maxillectomy, radiotherapy, steroids, and cyclophosphamide.
Implications:
- These cases highlight the clinicopathological difficulties in diagnosing and managing IP.
- The unpredictable and potentially aggressive behavior of IP necessitates individualized treatment strategies.
- Further research is needed to understand the pathogenesis and optimize treatment for this rare entity.
